References
- Munoz, A., Guichard, J. P. and Reginault, P (1994). Micronisedfenofibrate. Atherosclerosis, 110 (Suppl), S45–S48.
- Kirchgässler, K. U., Schmitz, H. and Bach, G. (1998). Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200 mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia. Clin. Drug Invest., 15, 197–204.
- Poulter, N. (1999). The impact of micronized fenofibrate on lipid subfractions and on reaching HDL-target levels in 7,098 patients with dyslipidaemia. Br. J. Cardiol., 6, 682–685.
- Adkins, J. C. and Faulds, D. (1997). Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs, 54, 615–633.
- Lantz, R. J., Jr (1990). Size reduction in pharmaceutical dosage forms. In Tablets (Eds Lieberman, H. A., Lachman, L. and Schwartz, J. B.), Vol. 2, Marcel Dekker, New York, 2nd edn, 112.
- Perkins, A. C., Wilson, C. G., Frier, M. et al. (1999). Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations. Int. J. Pharm., 186, 169–175.
- Channer, K. S. and Virjee, J. P. (1985). The effect of formulation on oesophageal transit. J. Pharm. Pharmacol., 37, 126–129.
- Marvola, M., Rajaniemi, M., Marttila, E., et al. (1983). Effect of dosage form and formulation factors on the adherence of drugs to the esophagus. J. Pharm. Sci., 72, 1034–1036.